Cipla Shares Surge 8% Despite Weak Q4 Earnings Amid Positive Outlook
Cipla soars 8% despite disappointing Q4; what's driving pharma stock?
Business Standard
Image: Business Standard
Cipla's shares rose by 8% to ₹1,432.35 following positive management commentary, despite a 54.6% year-on-year decline in Q4 net profit to ₹554.6 crore. The company anticipates a rebound in FY27, targeting $1 billion revenue from the US market and improved margins.
- 01Cipla's share price increased by 8% to ₹1,432.35 after positive management statements.
- 02The company reported a significant 54.6% drop in Q4 net profit year-on-year.
- 03Cipla aims for $1 billion revenue from the US in FY27, focusing on respiratory and peptide launches.
- 04Analysts have a cautious outlook due to ongoing challenges and delayed revenue contributions.
- 05The stock's recent rally has seen a recovery of 23% from its 52-week low.
Advertisement
In-Article Ad
Cipla's share price surged 8% to ₹1,432.35 on the Bombay Stock Exchange (BSE) following optimistic comments from management, despite disappointing Q4 results. The pharmaceutical company reported a 54.6% decline in consolidated net profit to ₹554.6 crore for the fourth quarter of the financial year 2025-26, down from ₹1,221.8 crore in the same period last year. Revenue also fell by 2.8% to ₹6,541.2 crore due to the absence of high-margin products and increased operational costs. Looking ahead, Cipla's management is optimistic about revenue growth, projecting $1 billion from the US market in FY27, supported by upcoming respiratory and peptide product launches. Analysts remain cautious, with some maintaining a 'Neutral' rating on the stock due to ongoing challenges and the need for successful execution of new launches to improve margins and revenue.
Advertisement
In-Article Ad
The fluctuations in Cipla's stock price may affect investor sentiment and market confidence in the pharmaceutical sector, potentially influencing future investments and employment opportunities within the company.
Advertisement
In-Article Ad
Reader Poll
Do you believe Cipla can recover from its recent earnings decline?
Connecting to poll...
More about Cipla
Cipla Reports 55% Drop in Q4 Net Profit Amidst Mixed Annual Performance
The Economic Times • May 14, 2026
Cipla Expands Biosimilars Pipeline Amidst Mixed Financial Performance
Mint • May 13, 2026
Cipla Reports 55% Drop in Q4 Profit Amid US Market Challenges and Increased R&D Spending
Business Standard • May 13, 2026
Read the original article
Visit the source for the complete story.